Drug Price Trends for CYRED EQ

Average Pharmacy Cost for CYRED EQ

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
CYRED EQ 28 DAY TABLET	50102-0254-21	0.14401	EACH	2025-03-19
CYRED EQ 28 DAY TABLET	50102-0254-23	0.14401	EACH	2025-03-19
CYRED EQ 28 DAY TABLET	50102-0254-21	0.13493	EACH	2025-02-19
CYRED EQ 28 DAY TABLET	50102-0254-23	0.13493	EACH	2025-02-19
CYRED EQ 28 DAY TABLET	50102-0254-23	0.12072	EACH	2025-01-22
CYRED EQ 28 DAY TABLET	50102-0254-21	0.12072	EACH	2025-01-22

Market Analysis and Price Projections for Cyred EQ

Introduction

Cyred EQ is a combined oral contraceptive containing desogestrel and ethinyl estradiol, indicated for the prevention of pregnancy. To understand the market dynamics and price projections for Cyred EQ, it is essential to analyze various factors including its pharmacokinetics, market competition, and broader pharmaceutical trends.

Pharmacokinetics and Efficacy

Cyred EQ is highly effective in preventing pregnancy, with a user-efficacy pregnancy rate of 1.12 per 100 women-years in clinical trials involving 1,195 subjects and 11,656 cycles[1][4].

• Absorption and Metabolism: Desogestrel and ethinyl estradiol are rapidly absorbed, with maximum concentrations reached within 1.4 to 1.5 hours. The relative bioavailability of ethinyl estradiol is approximately 83% after a single dose[1][4].

Market Competition

The oral contraceptive market is competitive, with various products available.

• Alternatives: Other popular oral contraceptives include Mirena (levonorgestrel) and Nexplanon (etonogestrel). These alternatives have different active ingredients and administration methods (e.g., intrauterine device for Mirena and subdermal implant for Nexplanon)[5].

Pricing Trends in the Pharmaceutical Market

The overall pharmaceutical market is experiencing price inflation, which can impact the pricing of Cyred EQ.

• General Pharmaceutical Price Inflation: According to Vizient, Inc., the pharmaceutical market is projected to see a 3.8% price increase, driven in part by specialty pharmaceuticals. This trend could influence the pricing of all medications, including oral contraceptives[2].

Specialty Pharmaceuticals and Market Impact

While Cyred EQ is not classified as a specialty pharmaceutical, the broader trends in this segment can affect the entire pharmaceutical market.

• Specialty Pharmaceuticals: The increasing utilization of weight loss drugs and gene therapies is driving up costs. However, these trends are more relevant to high-cost, complex conditions rather than routine medications like oral contraceptives[2].

Biosimilars and Generic Impact

The impact of biosimilars and generics on the pharmaceutical market can also influence the pricing of branded drugs.

• Biosimilars: Although biosimilars are more relevant to biologic drugs, the trend of increasing biosimilar use can lead to pricing pressures on branded products across the market. For example, biosimilar adalimumab products are expected to gain market share, potentially reducing the prices of branded biologics[2].

Price Projections for Cyred EQ

Given the current market dynamics, here are some key points to consider for price projections:

• Stable Pricing: Oral contraceptives like Cyred EQ tend to have relatively stable pricing compared to specialty pharmaceuticals. The efficacy and established market presence of Cyred EQ suggest that its pricing may not fluctuate significantly in the short term[1][4].

• Competition and Market Forces: The presence of alternative oral contraceptives and the overall competitive landscape may keep prices in check. Manufacturers may need to balance pricing with the need to maintain market share[5].

• Pharmaceutical Market Trends: While the broader pharmaceutical market is seeing a 3.8% price increase, this trend is more pronounced in specialty pharmaceuticals. Oral contraceptives, being a more commoditized product, are less likely to see such significant price hikes[2].

Conclusion

Cyred EQ, as a well-established oral contraceptive, is likely to maintain stable pricing due to its efficacy, established market presence, and the competitive nature of the oral contraceptive market. While broader pharmaceutical trends may influence pricing, the impact on Cyred EQ is expected to be minimal.

Key Takeaways

• Efficacy: Cyred EQ is highly effective in preventing pregnancy.
• Pharmacokinetics: Rapid absorption and stable bioavailability.
• Market Competition: Faces competition from other oral contraceptives like Mirena and Nexplanon.
• Pricing Trends: Stable pricing expected due to market competition and the commoditized nature of oral contraceptives.
• Broader Market Impact: Minimal impact from broader pharmaceutical trends such as specialty pharmaceutical price increases.

FAQs

Q: What is the primary indication for Cyred EQ? A: Cyred EQ is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception[1][4].

Q: How effective is Cyred EQ in preventing pregnancy? A: Cyred EQ has a user-efficacy pregnancy rate of 1.12 per 100 women-years[1][4].

Q: What are the active ingredients in Cyred EQ? A: Cyred EQ contains desogestrel and ethinyl estradiol[1][4].

Q: How does the pricing of Cyred EQ compare to other oral contraceptives? A: The pricing of Cyred EQ is competitive with other oral contraceptives like Mirena and Nexplanon, and is influenced by market competition rather than broader pharmaceutical trends[5].

Q: Are there any significant price increases projected for Cyred EQ? A: No significant price increases are projected for Cyred EQ, given its stable market position and the competitive nature of the oral contraceptive market[2].

Sources

1. Drugs.com - Cyred EQ: Package Insert / Prescribing Information
2. Vizient, Inc. - Vizient Projects 3.8% Drug Price Increase Driven by Specialty Pharmaceuticals
3. GlobalData - NSCLC MARKET - Global Drug Forecast & Market Analysis to 2025
4. DailyMed - CYRED EQ- desogestrel and ethinyl estradiol
5. Drugs.com - Cyred EQ Alternatives Compared